European Commission Grants Final Approval for Gan & Lee and Sandoz's Lantus Biosimilar, Ondibta, for Market Launch
Targeting the European Market Through Global Partnership
Ondibta (insulin glargine), a basal insulin biosimilar developed by China's Gan & Lee Pharmaceuticals and commercialized by Sandoz, has received final marketing authorization from the European Medicines Agency (EMA) and the European Commission (EC). This approval is considered a prime example of the successful partnership between Sandoz, a leading player in the global biosimilar market, and Gan & Lee, a Chinese pharmaceutical company specializing in insulin development. Based on a global agreement signed in 2018, the two companies have been continuously developing a range of insulin analog products, and with the approval in the European market, they are poised to aggressively expand into global advanced markets. This represents a significant turning point that will substantially enhance their commercial position within the vast European basal insulin prescription market.
Demonstrating Equivalence Through Large-Scale Global Phase 3 Clinical Trials
Ondibta was developed using Sanofi's blockbuster basal insulin, Lantus, as a reference drug, and has demonstrated clinical efficacy and reliability. Through a large-scale, multinational Phase 3 clinical trial involving over 1,100 patients with Type 1 and Type 2 diabetes in Europe and the United States, it has been thoroughly proven to be 'highly similar' in terms of efficacy, safety, and immunogenicity compared to the original drug. In particular, the glucose clamp assessment, a standard technique for evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) equivalence of insulin, confirmed no statistically significant difference compared to the original Lantus. The final approval from European regulatory authorities confirms the drug's high quality control standards and sophisticated manufacturing processes.
Restructuring the European Insulin Market and Price Pressure
The current European insulin market is characterized by intense competition among existing biosimilars, including Sanofi's Lantus and subsequent formulations, as well as Abasaglar, launched by Eli Lilly and Boehringer Ingelheim. With the entry of Ondibta, which combines Sandoz's extensive Western marketing channels and Gan & Lee's cost-effective large-scale production infrastructure, significant downward pressure on existing drug prices is expected. The emergence of this powerful alternative can lead to meaningful cost savings for public healthcare budgets while providing patient-centric benefits by ensuring affordable access to medication for diabetes patients. Existing market leaders will inevitably have to devise strategies to defend their market share in the face of Ondibta's aggressive pricing policy.
Medium- to Long-Term Growth Momentum and Global Portfolio Expansion for Both Companies
Gan & Lee Pharmaceuticals, which had previously focused on the domestic market, has achieved a significant milestone with the successful European approval of Ondibta, establishing its first export model to Western global markets. Sandoz, which is jointly commercializing the product, will also strengthen its high-margin biosimilar portfolio, further solidifying its independent growth momentum after its spin-off from Novartis. The two companies plan to expedite the global approval process for other basal insulin glargine, as well as ultra-fast-acting insulins such as lispro and aspart. This will be a key asset for creating long-term synergy and fostering the sustainable growth of their combined revenue pipeline.
In the global insulin glargine market, valued at approximately $7 billion annually, where the original drug, Sanofi's Lantus, is experiencing declining sales, the approval of Gan & Lee's Ondibta, which has completed Phase 3 clinical trials, will serve as a direct trigger for intensifying price competition in the basal insulin biosimilar sector. From an investor's perspective, it is important to monitor the speed of market penetration through Sandoz's sales and distribution network in the European market, where Eli Lilly's Abasaglar and other competitors have already established a presence, as well as the resulting price reduction. For researchers and industry professionals, the fact that a Chinese biotech company's high-quality, large-scale insulin production technology has passed the stringent CMC (Chemistry, Manufacturing, and Controls) barrier of the European regulatory agency, EMA, and reached the commercialization stage, highlights the importance of manufacturing cost competitiveness. In the medium to long term, the approval speed of subsequent analog pipelines, such as lispro and aspart, will determine the diversification of revenue and the enhancement of corporate value for both Sandoz and Gan & Lee.
Source: EMA (ema)